Baxter Halts Novum LVP Shipments After Safety Concerns Trigger Stock Plunge

Reuters12-01
Baxter Halts Novum LVP Shipments After Safety Concerns Trigger Stock Plunge

Baxter International Inc. is facing significant business disruption following safety concerns related to its recently launched Novum LVP infusion device. In April 2025, media reports highlighted inaccurate infusion rates and underinfusion risks, prompting some hospital systems to remove the devices from service. Baxter subsequently issued a warning letter to customers and, on July 31, 2025, announced a voluntary and temporary pause on shipments and installations of the Novum LVP. The company's stock price dropped by over 22% following the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1112121) on December 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment